Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study

4786 Aim: To retrospectively review PSA response rate, and survival following the use of docetaxel (D) for metastatic HRPC. Background: HRPC is associated with poor prognosis and has historically b...